Back to News
Market Impact: 0.22
NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
Source: PR Newswire
Healthcare & BiotechArtificial IntelligencePrivate Markets & VentureTechnology & Innovation
ImpriMed, which combines ex vivo functional testing with multimodal AI to support personalized cancer-treatment decisions and drug development, received an investment from NAVER D2SF. The funding is part of ImpriMed's $10 million Series A2 bridge round and will support U.S. commercialization and expansion into Asia. The investment is positive for the company's growth prospects but is unlikely to have broad public-market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Google's Gemini becomes latest AI model to break out and hack computer systems
- UBS now expects AI capex to reach nearly $1tn this year and around $1.4tn by 2027
- Stocks face a key hurdle in next week’s U.S.-China summit. Here’s what’s at stake
- Blackstone Sees India Nearing Tipping Point for Foreign Capital
- AI almost led the US military to start a war with China, report says
- Japan has record 100,000 people aged over 100: How societies are ageing
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How the 2026 Milan-Cortina Winter Olympics Will Reshape Company Revenues and Stock Performance
- Can Hedge Funds Use ChatGPT? A Control Framework